Clinical Scenario of the Metabolic Syndrome

Brede, Swantje; Serfling, Georg; Klement, Johanna; Schmid, Sebastian; Lehnert, Hendrik

doi:10.1159/000449028

Cited by 21 publications

(20 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Metabolic syndrome (MetS) is a cluster of metabolic disorders and associated with obesity, insulin resistance, hypertension, and dyslipidemia, and it increases risks for cardiovascular diseases (CVDs) and type 2 diabetes mellitus (T2DM). [1][2][3][4][5] In the past decade, the prevalence of MetS has increased to 34.7% in USA, and to 24.5% in China. 6,7 MetS has led to a 1.5 to 2.5 fold increase in the mortality from CVD that makes a major public health problem today.…”

Section: Introductionmentioning

confidence: 99%

Circulating C1q/TNF‐related protein isoform 15 is a marker for the presence of metabolic syndrome

Wang

et al. 2018

Diabetes Metabolism Res

View full text Add to dashboard Cite

Background C1q/TNF‐related protein isoform 15 (CTRP15) has been reported to be related to glucose and lipid metabolism, but the results are inconsistent. Metabolic syndrome (MetS) is a cluster of metabolic disorders. The aim of this study is to determine circulating CTRP15 levels in individuals with MetS and investigate the association among circulating CTRP15 and markers for MetS as well as insulin resistance. Methods A total of 341 individuals were recruited for this cross‐sectional study. These subjects were screened for MetS. Serum CTRP15 concentrations were measured by ELISA. Results Serum CTRP15 levels were significantly higher in MetS individuals relative to those of the healthy individuals. Circulating CTRP15 correlated positively with WHR, BMI, SBP, FAT %, 2 h‐BG, FIns, 2 h‐Ins, TG, FFA, HbA1c, HOMA‐IR, and AUCglucose, while negatively with HDL‐C and ISI. Multiple linear regression showed that HOMA‐IR and HDL‐C are independently related factors influencing serum CTRP15 concentrations. In addition, binary logistic regression analysis showed that serum CTRP15 concentrations were significantly related to MetS. When the mean concentrations of circulating CTRP15 in MetS subjects were stratified by the number of components of the MetS, circulating CTRP15 was found to increase progressively with increasing number of the MetS components. Finally, ROC curve analysis showed that the best cutoff values for circulating CTRP15 to predict MetS and insulin resistance were 63.6 and 64.0 μg/L. Conclusions Serum CTRP15 concentrations were associated with the key components of MetS and insulin resistance.

show abstract

Section: Introductionmentioning

confidence: 99%

Circulating C1q/TNF‐related protein isoform 15 is a marker for the presence of metabolic syndrome

Wang

et al. 2018

Diabetes Metabolism Res

View full text Add to dashboard Cite

show abstract

“…However, our results revealed that the most important factor that affects metabolic dysregulation in obesity is IR, which probably appears to be predominantly early stage of the Met-HO. There is evidence that an accumulation of visceral adiposity tissue (VAT) might associate with over-production of pro-inflammatory cytokines including hs-CRP, leptin and vistafin and induce IR (Brede et al, 2016). Therefore, infiltration of the sub-intima by LDL cholesterol may induce production of free radicals, oxidation of cytoskeleton and membrane vesiculation of endothelial cells.…”

Section: Discussionmentioning

confidence: 99%

Circulating apoptotic endothelial cell-derived microparticles are predicted metabolically unhealthy obesity

Berezin

Kremzer

Berezina³

et al. 2017

Biomed Res Ther

View full text Add to dashboard Cite

Introduction: Circulating apoptotic endothelial cell-derived micro particles (EMPs) are a marker of endothelial dysfunction and cardiovascular (CV) risk in type 2 diabetes mellitus patients. There is evidence regarding association between apoptotic EMP number and CV disease in obese individuals. The aim of the study to investigate whether increased number of circulating apoptotic EMPs may predict transformation of Met-HO into Met-UHO. Methods: The study was retrospectively evolved 89 patients with established abdominal obesity (47 patients with Met-UHO determined as MetS and 42 subjects with Met-HO) from the large cohort of abdominal obesity patients (n=268). Thirty five healthy volunteers matched for age and sex were involved in the study as a control cohort. Obesity-related biomarker (adiponectin, leptin, vistafin) and EMPs were measured at baseline. Flow cytometry was used to determine EMPs with immune phenotype CD31+/ annexin V+ and CD144+/annexin V+. Results: There was not found a significant difference between numbers of EMPs labeled CD31 + / Annexin V + in Met-UHO and Met-HO patients, while Met-UHO patients had a significantly increased level of circulating CD144 + / Annexin V + compared with Met-HO individuals. Multivariate logistic regression analysis has revealed the HOMA-IR, number of CV risk factors, serum leptin and hs-CRP independently predicted numbers of circulating CD31 + / Annexin V + and CD144 + / Annexin V + EMPs in Met-UHO. In Met-HO patients HOMA-IR remained an independent predictor of increased numbers of circulating CD31 + / Annexin V + and CD144 + / Annexin V + EMPs. Conclusion: in the investigation we found that the increased number of CD31 + /Annexin V + and CD144 + / Annexin V + EMPs added to the based predictive model (HOMA-IR) may predict transformation of Met-HO into Met-UHO.

show abstract

“…Obesity is detrimental to people because it comes with more disorders like an increase in breathing rate, an abnormal increase in heart rate, and increases in blood pressure disrupting the normal life of humans, making them un it. To de ine novel methods of avoidance and therapy, the pathogenesis of obesity is crucial (Brede, 2016).…”

Section: Pathogenesismentioning

confidence: 99%

Role of various signalling mechanism in pathogenesis and therapeutics of obesity

Prashar

Patel

2019

ijrps

View full text Add to dashboard Cite

This paper is a summary of appetite pathogenesis, therapy, and various mechanisms involved in obesity. Pathogenesis related to obesity deals with energy expenditure physiology and energy intake. The pathogenesis of obesity also contributes to energy regulation. Obesity usually happens when the consumption of energy is more than energy expenditure. It also includes relative research of monogenetic triggers contributing to deficiency of nutrition consumption and depression in key legislation. Obesity therapy involves the finding of hormones, neuropeptides, receptors, and transcription factors that involve the growth and regulation of eating behaviour, metabolic rate, and adipocyte. This paper also deals with various pathways which have a huge scientific basis in research in obesity. This review also focusses on the relation the pathways share by bringing them under one preview to understand their importance in the research area of obesity. It also includes comparative research and study work, which included the role and importance of various mediators like PYY, Ghrelin, Leptin, Adiponectin, along with inflammatory mediators like TNF Alpha and Interleukins. An insight into the role of oxidative stress highlighting its role and importance in obesity is also reviewed. Obesity therapy overview as well as newer strategies are also discussed. It also includes the methodology of exploration and obesity treatment in a novel way. Overall the review is a blend that incorporates major problems along with the latest treatment strategies to understand the demonic nature of this disease.

show abstract

Clinical Scenario of the Metabolic Syndrome

Cited by 21 publications

References 80 publications

Circulating C1q/TNF‐related protein isoform 15 is a marker for the presence of metabolic syndrome

Circulating C1q/TNF‐related protein isoform 15 is a marker for the presence of metabolic syndrome

Circulating apoptotic endothelial cell-derived microparticles are predicted metabolically unhealthy obesity

Role of various signalling mechanism in pathogenesis and therapeutics of obesity

Contact Info

Product

Resources

About